USE OF GLYCOPYRROLATE FOR TREATING TACHYCARDIA
The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
1 - 50 . (canceled)
51 . An inhalable pharmaceutical composition comprising glycopyrrolate or a pharmaceutically acceptable salt thereof for use as a heart rate lowering agent, or for use as a heart rate suppression agent under resting conditions.
52 . An inhalable unit dose comprising the pharmaceutical composition as defined in claim 51 for use in the treatment or prophylaxis of tachycardia.
53 . The unit dose as defined in claim 52 , which comprises a capsule.
54 . The unit dose as defined in claim 52 , wherein the unit dose comprises a capsule made with hypromellose (HPMC) or another cellulose or cellulose derivative.
55 . An inhalation delivery device comprising one or more unit doses as defined in claim 52 for use in the treatment or prophylaxis of tachycardia.
56 . The delivery device as defined in claim 55 , wherein the delivery device is an inhaler.
57 . The delivery device as defined in claim 56 , wherein the delivery device is a dry powder inhaler, a pressurized metered dose inhaler, or a nebulizer.
58 . The delivery device as defined in claim 57 , wherein the device comprises means for protecting the composition from moisture.
59 . A pharmaceutical composition as defined in claim 51 , contained in a package which further comprises instructions for administering said composition to a patient in need of a heart rate lowering agent, or in anticipation of the need of a heart rate lowering agent.
60 . The pharmaceutical composition according to claim 59 , wherein the instructions are for administering said composition to a patient suffering from tachycardia or in need of prophylaxis of tachycardia.
61 . A method of treatment or prophylaxis of a condition or disorder characterised by an increased heart rate, said method comprising administering to a patient in need of such treatment or prophylaxis, an effective amount of an inhalable pharmaceutical composition comprising glycopyrrolate or a pharmaceutically acceptable salt thereof.
62 . The method according to claim 61 , wherein the composition is administered to a patient suffering from a respiratory condition selected from chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF) and related airway diseases.
63 . The method, according to claim 62 , wherein the patient has COPD.
64 . The method, according to claim 61 , wherein the patient has tachycardia that has been pharmaceutically induced.
65 . The method, according to claim 64 , wherein the tachycardia has been induced by administration of salbutamol.
66 . The method, according to claim 61 , wherein the patient has tachycardia that is induced by an endocrine disorder.
67 . The method, according to claim 61 , wherein the patient has a form of tachycardia selected from the group consisting of ventricular tachycardia, supraventricular tachycardia, atrial fibrillation, AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT) and junctional tachycardia.
68 . The method, according to claim 61 , wherein the patient has a resting heart rate of greater than 90 beats per minute.
69 . The method, according to claim 61 , wherein the glycopyrrolate or a pharmaceutically acceptable salt thereof comprises glycopyrronium bromide.
70 . The method, according to claim 61 , wherein glycopyrrolate is present within the composition in an amount of between 10 and 500 pg.
71 . The method, according to claim 70 , wherein glycopyrrolate is present within the composition in an amount of 20 pg.
72 . The method, according to claim 70 , wherein glycopyrrolate is present within the composition in an amount of 400 pg.
73 . The method according to claim 61 , wherein the glycopyrrolate is administered once daily.
74 . The method, according to claim 61 , wherein the pharmaceutical composition is formulated as a dry powder formulation.
75 . The method, according to claim 61 , wherein the composition additionally comprises a force control agent.
76 . The method, according to claim 75 , wherein the force control agent comprises a metal stearate, or a derivative thereof.
77 . The method, according to claim 76 , wherein the force control agent comprises zinc stearate, magnesium stearate, calcium stearate, sodium stearate or lithium stearate.
78 . The method, according to claim 77 , wherein the force control agent comprises magnesium stearate.
79 . The method, according to claim 61 , wherein the composition further comprises lactose.
80 . The method, according to claim 79 , wherein the composition comprises 1% (w/w) glycopyrronium bromide and 99% (w/w) lactose.
81 . The method, according to claim 79 , wherein the composition comprises 1.05% (w/w) glycopyrronium bromide, 98.8% (w/w) lactose and 0.15% (w/w) magnesium stearate, or 1% (w/w) glycopyrronium bromide, 98.8% (w/w) lactose and 0.2% (w/w) magnesium stearate.
82 . The method, according to claim 61 , wherein the composition further comprises indacateral.
83 . The method, according to claim 61 , wherein the composition further comprises a beta agonist.
84 . The method, according to claim 61 , wherein the patient is receiving concomitant treatment with a beta agonist.